NCT02184637 - A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

April 8, 2015

Study Completion Date

April 8, 2015

Conditions

Malaria, Vivax

Interventions

DRUG

Tafenoquine

A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally

DRUG

Dihydroartemisinin + Piperaquine tetraphosphate

"White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two σ letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally"

DRUG

Artemether + Lumefantrine

"Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally"

Trial Locations (1)

21225

GSK Investigational Site, Baltimore